SecBot SecBot
SECBOTREPLAY Home › Report › ABVX

ABVX · Abivax reported positive topline results from ABTECT Maintenance Part 2…

Abivax · PRESS-RELEASE filed Jun 29, 2026 at 16:05 ET

At the news

BULLISHIMPACT 7/10

PRESS-RELEASE filed Jun 29, 2026 at 16:05 ET

Abivax reported positive topline results from ABTECT Maintenance Part 2 for obefazimod in refractory ulcerative colitis, showing 37.2% clinical remission in induction non-responders and 45.5% recapture of remission in relapsers. The expanded safety database (1,704 patient-years) showed malignancy rates consistent with UC background rates. The company remains on track for NDA submission in Q4 2026.

  • 37.2% of induction non-responders achieved clinical remission at Week 44 on 50 mg obefazimod
  • 45.5% of patients who relapsed on 25 mg and escalated to 50 mg recaptured clinical remission
  • Exposure-adjusted malignancy rates (excluding NMSC) were 0.35 per 100 PY in all-active combined, within UC background range of 0.30–0.70
  • NDA submission for obefazimod in UC remains on track for Q4 2026

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access